This is the authors' abstract. We don't add key points for this paper.
HSPCs, which retain long-term engraftment and multilineage differentiation ability. After CAR T cell treatment, we confirmed resistance of epitope-edited haematopoiesis and concomitant eradication of patient-derived acute myeloid leukaemia xenografts. Furthermore, we show that multiplex epitope engineering of HSPCs is feasible and enables more effective immunotherapies against multiple targets without incurring overlapping off-tumour toxicities. We envision that this approach will provide opportunities to treat relapsed/refractory acute myeloid leukaemia and enable safer non-genotoxic conditioning.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Casirati et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: